知镜 Cognispect · 医学文献与研究工作台

SAMD9L-Related Syndrome

Raskind WH, Keel S, Allenspach EJ.
· 2026-08-20 · PMID 28570036

文献摘要

Clinical characteristics SAMD9L-related syndrome is a multisystemic disorder variably characterized by hematologic, immunologic, and neurologic involvement. Cytopenias affecting all hematopoietic lineages arise in a typically hypocellular marrow, range from mild to severe, and most often present in infancy or early childhood. Individuals have a predisposition to marrow failure, myelodysplasia, and myeloid leukemia, sometimes associated with monosomy 7. Immunodeficiency most often consists of B and NK cell deficiencies. The neurologic manifestations typically have later onset – during adolescence or less often adulthood – and include slowly progressive cerebellar ataxia, sensorimotor axonal polyneuropathy, dysautonomia, and paracentral retinal dysfunction. Even before these manifestations are apparent, brain imaging may show cerebellar atrophy and periventricular and deep white matter abnormalities and/or cysts. SAMD9L-associated autoinflammatory subtype (SAAD) is a severe autoinflammatory phenotype with infantile or neonatal onset caused by pathogenic SAMD9L variants that truncate the autoregulatory domain but preserve the protein's enzymatic function. This phenotype may include cytopenias, skin inflammation, lipoatrophy, early-onset interstitial lung disease, and basal ganglia calcifications. SAMD9L-related syndrome is characterized by frequent somatic genetic rescue in the hematopoietic system that eliminates or inactivates the mutated allele, resulting in improvement of cytopenias but also predisposing to clonal hematopoiesis and, in some individuals, premalignant evolution. Diagnosis/testing The diagnosis of SAMD9L-related syndrome is established in a proband with a heterozygous germline gain-of-function pathogenic variant in SAMD9L identified by molecular genetic testing. Acquired monosomy 7 or uniparental disomy of 7q can reduce the variant allele frequency of a germline SAMD9L pathogenic variant in blood-, bone marrow-, buccal mucosa-, or saliva-derived DNA, leading to failure to identify the pathogenic variant or misclassification as somatic. In some instances, germline testing of a non-hematopoietic tissue may be needed. Management Treatment of manifestations: Provide supportive care with red cell and/or platelet transfusions as needed; evaluate for additional reversible causes of hematopoietic cytopenias; manage neutropenia and immune deficiencies per standard approaches; consider hematopoietic stem cell transplantation (HSCT) and/or chemotherapy for myelodysplasia, leukemia, severe immune deficiency, or autoinflammatory manifestations. Note: HSCT does not appear to halt the progression of non-hematologic manifestations. Consider corticosteroids or JAK inhibitors for autoinflammatory manifestations; consider immunoglobulin replacement to reduce infections that may exacerbate disease. Provide supportive management for ataxia to maintain/improve independence with ambulation and other activities of daily living and to prevent falls and injury; consider a trial of riluzole to improve ataxia symptoms; referral for speech and language therapy, including evaluation for alternative communication methods, as clinically indicated for dysarthria; modify food consistency to reduce aspiration risk in individuals with dysphagia; assess nutrition status and provide dietary or vitamin supplementation as needed for weight loss or poor weight gain. Surveillance: There are no established surveillance guidelines but suggested approaches include: clinical evaluation with a hematologist every six to 12 months depending on age and presence of cytopenias or monosomy 7; complete blood count with differential every six to 12 months; consider bone marrow evaluation at baseline and annually based on shared decision making with the individual and family; consider more frequent CBC and bone marrow monitoring for concerning findings, such as new or worsening cytopenias or high-risk somatic changes (e.g., monosomy 7); annual immunologic evaluation including lymphocyte subset analysis (T , B , and NK cell immunophenotyping, CD45RA/RO T cell subsets) and quantitative immunoglobulin analysis. Evaluation with a neurologist as needed to assess for ataxia and progression of impairments including dysphonia and dysphagia and signs and symptoms of aspiration risk. If relevant, consider referral for speech therapy, alternative communication methods, physical or occupational therapy, or ophthalmologic evaluation. Agents/circumstances to avoid: Nonsteroidal anti-inflammatory agents, anticoagulants, and thrombolytic agents are contraindicated if severe thrombocytopenia is present and otherwise should be used with caution given the fluctuating nature of the cytopenias; avoid alcohol and centrally acting medications that cause sedation, which can increase problems with gait and coordination. Evaluation of relatives at risk: Offer molecular genetic testing for the familial SAMD9L pathogenic variant to asymptomatic at-risk relatives to identify those who would benefit from hematologic surveillance and early treatment of severe cytopenias or myeloid malignancy. Note: (1) If a SAMD9L pathogenic variant is not detected in DNA from an at-risk family member's blood sample, additional testing using DNA derived from non-hematopoietic tissue can be considered. (2) Somatic genetic changes may result in a false negative molecular result when testing leukocyte DNA. Pregnancy management: Anemia, thrombocytopenia, or neutropenia may increase the risk of pregnancy complications. Genetic counseling SAMD9L-related syndrome is an autosomal dominant disorder often caused by a de novo germline pathogenic variant. Some individuals have the disorder as the result of a pathogenic variant inherited from a parent who may or may not have apparent features of the syndrome. Marked intrafamilial variation in age of onset, neurologic manifestations, and hematologic abnormalities has been observed in all multigenerational families reported to date. A proband may appear to be the only affected family member for several reasons: (1) failure to recognize the disorder in family members with no neurologic manifestations (or subtle neurologic manifestations) and/or episodic hematologic manifestations; (2) reduced penetrance (often resulting from a "protective" second genetic event); or (3) early death of the parent before the onset of symptoms or late onset of the disease in the affected parent. An apparently negative family history cannot be confirmed unless molecular genetic testing of both parents using DNA from a non-hematopoietic tissue demonstrates absence of the germline SAMD9L pathogenic variant identified in the proband. Each child of an individual with SAMD9L-related syndrome has a 50% chance of inheriting the SAMD9L pathogenic variant. Once the germline SAMD9L pathogenic variant has been identified in an affected family member, molecular genetic testing of at-risk relatives and prenatal/preimplantation genetic testing are possible.

在知镜精读原文来源

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。